AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00969150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
Study NCT01369394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: Computer-based tailoring system
Description: Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website.
Study NCT01369394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Computer-based tailoring system
Description: Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website.
Study NCT05135507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An integrated parenting intervention for families of children with developmental disabilities
Description: Deliver three training modules to parent and track program usage, psychological flexibility, parents' stress, parents mindfulness, and child behavior
Study NCT04192968 — intervention group
Intervention type: OTHER
Intervention: Additional exams
Description: * Cortical auditory evoked potentials Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.~* Recording of cortical auditory evoked potentials in response to a click~* Realization of electrical potentials via the implant Followed up once a year during a visit scheduled for usual care, for 3 years, that to say up to 6 years post-implant.
Study NCT01167010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol/Budesonide
Description: formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
Study NCT01167010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foraseq
Description: foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
Study NCT01167010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alenia
Description: Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
Study NCT01847105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RevitaLens
Description: Multi-purpose disinfecting solution
Study NCT01847105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OptiFree PureMoist
Description: Multi-purpose disinfecting solution
Study NCT00793572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo transplantation
Study NCT00793572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study NCT00793572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV
Study NCT00793572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT00793572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00793572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00793572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT00793572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00793572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo transplantation
Study NCT00793572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo transplantation
Study NCT00793572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Syngeneic Bone Marrow Transplantation
Description: Undergo transplantation
Study NCT00793572 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo radiotherapy
Study NCT00123097 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chlorinated polyethylene elastomer
Description: Chlorinated polyethylene
Study NCT00123097 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chlorinated polyethylene elastomer
Description: Chlorinated polyethylene
Study NCT02159222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional physical therapy
Study NCT03082573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H.P. Acthar gel
Description: H.P. Acthar gel in treatment of Refractory RA
Study NCT02819999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00902993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Solution, oral single and multiple dose
Study NCT00902993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03250078 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI/MRCP
Description: An MRI/MRCP plus IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
Study NCT03887520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood draw for Lp(a)
Description: Collect sample for Lipoprotein(a) testing
Study NCT02361424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT00864
Description: PXT00864 is a fixed-dose combination of baclofen and acamprosate
Study NCT02361424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04592172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime Routine Education
Description: The intervention aims to promote healthy sleep and improved developmental outcomes in infants. Individualized bedtime routine education, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling will be implemented by research assistants at the 12-month well-child visit. Reinforcement of the bedtime routine education will be implemented at the 15-month visit. Each individualized bedtime routine will incorporate 3-5 steps and a bedtime routine chart depicting those steps will be created and provided to the families. Families will receive materials for their bedtime routines, including a CuddleBright kit, 1-2 additional bedtime books, toothbrush/toothpaste , and the created bedtime chart. On top of that, families will also receive a children's book provided by Reach Out and Read through the study period.
Study NCT00575432 — intervention group
Intervention type: RADIATION
Intervention: diffusion MRI
Description: diffusion MRI
Study NCT00575432 — intervention group
Intervention type: RADIATION
Intervention: BOLD MRI
Description: BOLD MRI
Study NCT00575432 — intervention group
Intervention type: OTHER
Intervention: Clinical Outcome
Description: Clinical outcome
Study NCT03102021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin
Description: 500 units/kg daily for 3 days at onset of acute kidney injury
Study NCT03102021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline 10 ml for 3 days
Study NCT00432107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APO866
Description: APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
Study NCT03814291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 0.05mg/eye;Intraocular injection
Study NCT03814291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 0.15mg/eye;Intraocular injection
Study NCT03814291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 0.5mg/eye;Intraocular injection
Study NCT03814291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 1mg/eye;Intraocular injection
Study NCT03814291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 2mg/eye;Intraocular injection
Study NCT03814291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 4mg/eye;Intraocular injection
Study NCT02187601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPBA System
Description: MPBA is the new generation Multi Purpose Breath Analyzer
Study NCT02187601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreathID
Description: BreathID is the name of the original Exalenz breath analyzer system
Study NCT02335723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alteco LPS Adsorber
Description: Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.~Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species.
Study NCT02335723 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
Study NCT00391274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
Study NCT00391274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
Study NCT00775112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pillow
Description: use of pillow for lumbar punctures
Study NCT00623662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative glucose infusion
Description: Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
Study NCT02066974 — intervention group
Intervention type: GENETIC
Intervention: hepatoma requiring radiotherapy
Description: hepatoma requiring radiotherapy
Study NCT03138395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: droplet digital PCR
Description: This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses.
Study NCT02543008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical activity plus thoracic mobilization
Description: Information already included in arm/group descriptions.
Study NCT02543008 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Information already included in arm/group descriptions.
Study NCT02543008 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Information already included in arm/group descriptions.
Study NCT04307693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir / Ritonavir tablet
Study NCT04307693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine sulfate
Description: Hydroxychloroquine sulfate tablet
Study NCT02548494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
Study NCT02548494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV insulin
Description: The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
Study NCT02548494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV insulin
Description: The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
Study NCT02548494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electrolyte Correction
Description: If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
Study NCT02548494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrolyte Correction
Description: If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
Study NCT02548494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Correction of Fluid Loss
Description: Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~* Administer 1-3 L during the first hour.~* Administer 1 L during the second hour.~* Administer 1 L during the following 2 hours~* Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings
Study NCT02548494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correction of Fluid Loss
Description: Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~* Administer 1-3 L during the first hour.~* Administer 1 L during the second hour.~* Administer 1 L during the following 2 hours~* Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings
Study NCT04648345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinal plane block
Description: After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.
Study NCT04648345 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector spinal plane block
Description: After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.
Study NCT04648345 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinal plane block
Description: After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.
Study NCT01168531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: pregabalin: 300 mg/day, po, from operative day until third postoperative day.
Study NCT01168531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone 16 mg, intravenous, before induction of anesthesia
Study NCT01168531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vitamin B complex formula
Study NCT01338493 — intervention group
Intervention type: PROCEDURE
Intervention: lumbar spinal arthroplasty + Maverick™
Description: All patients will be subjected to a lumbar spinal arthroplasty. The anterior lumbar spine is approached through either a transperitoneal or retroperitoneal exposure. A complete anterior discectomy is performed and the Maverick™ Artificial Disc System is inserted to replace the damaged lumbar intervertebral disc.
Study NCT01472081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01472081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study NCT01472081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study NCT01472081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT00623662 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preoperative normal saline infusion
Description: Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
Study NCT02124512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD
Description: Study Drug dosing will be 80 mg SSD once daily
Study NCT02124512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 80 mg placebo once daily
Study NCT01735669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Study NCT01735669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Study NCT00541034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00541034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00541034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentostatin
Study NCT03642236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.
Study NCT03642236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.
Study NCT04506489 — intervention group
Intervention type: OTHER
Intervention: Psychological investigation
Description: Psychological tests, psychological interviews.
Study NCT02165293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7033877 + Bronchoscopy
Description: Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
Study NCT01437644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin intramuscular injection
Description: A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo.
Study NCT01437644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: botulinum toxin intramuscular injection
Description: A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo.
Study NCT02144506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T&E
Study NCT02144506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTAGO
Study NCT02435680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: taken by I.V
Study NCT02435680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: taken by I.V
Study NCT02435680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: taken by I.V